Definitional Guide

What Is MQSA?

The Mammography Quality Standards Act: explained plainly for the breast imaging professionals who work under it every day.

Last Reviewed: August 25, 2026

Federal Law, 1992FDA EnforcedAnnual Inspections2024 Final Rule in Effect

MQSA in Plain Language

MQSA stands for the Mammography Quality Standards Act: a federal law enacted by Congress in 1992 and significantly strengthened in 1998. MQSA establishes national minimum quality standards for every facility in the United States that performs mammography.

Before MQSA, mammography quality varied dramatically from facility to facility. Equipment maintenance, technologist qualifications, radiologist experience, and the accuracy of reporting were inconsistent across the country. MQSA was created to address that variation and ensure that patients receiving mammograms, regardless of where they live, receive a consistent standard of care.

Under MQSA, every accredited mammography facility must meet federal standards across four areas: equipment and quality control, personnel qualifications, recordkeeping and reporting, and medical outcome auditing. Compliance is verified through annual, unannounced inspections by FDA-certified inspectors.

1992

Year Enacted

~8,800

Certified U.S. Facilities

Annual

Inspection Frequency

Sept 2024

2024 Final Rule Effective

What MQSA Requires: The Four Pillars

01

Equipment & Quality Control

All mammography equipment must be FDA-approved and maintained to MQSA standards. Facilities must conduct daily, weekly, monthly, and quarterly quality control tests with documented results. Medical physicists must perform annual equipment surveys. QC records must be retained and available for inspection.

02

Personnel Qualifications

Interpreting physicians must meet initial training and ongoing continuing experience requirements (60 mammograms per month minimum average). Radiologic technologists must hold ARRT certification (or equivalent) and meet mammography-specific continuing education requirements. Medical physicists must hold advanced training credentials specific to mammography. All credentials must be documented and current.

03

Recordkeeping & Patient Reporting

Facilities must issue written reports to referring physicians and written lay summaries to patients within 30 days (or sooner for abnormal findings). Since the 2024 Final Rule, lay letters must include standardized breast density notification language. All mammography images and reports must be retained for a minimum of 5 years (10 years if no prior mammograms are on file).

04

Medical Outcome Audit

MQSA requires a documented medical audit program that tracks positive mammography findings, correlates assessments with biopsy results and pathology outcomes, and measures key performance indicators, including recall rate, cancer detection rate, and positive predictive values (PPV1, PPV2, PPV3). Audit data must be analyzed annually and compared against established benchmarks. Individual interpreting physician data must be tracked and reviewed.

Current Regulation

The MQSA 2024 Final Rule

On March 9, 2023, the FDA published the most comprehensive update to MQSA regulations since 1999. The new rule took effect September 10, 2024. Key changes include:

  • Mandatory breast density notification in lay letters to all patients using FDA-approved standardized language
  • Updated medical audit requirements with revised tracking metrics and benchmarking expectations
  • Revised personnel qualification standards, including modified continuing experience requirements
  • Modernized recordkeeping, electronic record requirements, and patient access provisions
  • New corrective action and follow-up requirements for findings outside performance benchmarks

The breast density notification requirement is the most operationally significant change for most facilities.

Every lay letter produced after September 10, 2024 must include one of four FDA-prescribed breast density paragraphs based on the patient’s reported density classification. Facilities that had not updated their lay letter templates by the effective date were immediately out of compliance.

MQSA: Frequently Asked Questions

Detailed answers to the questions breast imaging professionals ask most often about MQSA requirements, inspections, and compliance.

MQSA stands for the Mammography Quality Standards Act. It is a federal law enacted by the United States Congress in 1992 and significantly amended in 1998. MQSA establishes national quality standards for mammography facilities, equipment, personnel, and reporting practices.

MQSA's purpose is to ensure that mammography services in the United States meet consistent quality standards that protect patients, specifically by ensuring that mammograms are performed by qualified personnel on properly maintained and calibrated equipment, that results are interpreted by credentialed radiologists, and that patients and referring physicians receive timely written reports. The law was designed to address wide variation in mammography quality that existed prior to its enactment.

MQSA is enforced by the U.S. Food and Drug Administration (FDA), which has regulatory authority over all mammography facilities in the country. The FDA may delegate inspection authority to approved accreditation bodies and state programs. The FDA retains authority to issue sanctions, suspensions, and civil monetary penalties for non-compliance.

An MQSA inspection typically covers: equipment performance and calibration records, quality control (QC) test results, personnel qualification documentation (for radiologists, technologists, and medical physicists), medical audit program records, patient notification and lay letter procedures, clinical image quality, and recordkeeping systems. Inspections are conducted annually by FDA-certified inspectors and are unannounced.

MQSA establishes separate qualification standards for three categories of personnel: interpreting physicians (radiologists who read mammograms) must meet initial training and continuing experience requirements; radiologic technologists who perform mammography must hold ARRT certification or equivalent and meet continuing education requirements; and medical physicists who perform mammography quality control testing must hold specific advanced training and experience credentials.

MQSA requires every accredited mammography facility to maintain a medical audit system that tracks outcomes and correlates pathology results with interpreting physicians' mammographic assessments. The audit must track: all positive mammography findings (BI-RADS® 0, 4, 5); biopsy results; cancer outcomes; and key performance indicators including recall rate, cancer detection rate, and positive predictive values (PPV1, PPV2, PPV3). Results must be analyzed at least annually and compared against established benchmarks.

MQSA requires all mammography facilities to be accredited by an FDA-approved accreditation body. Currently, the American College of Radiology (ACR) is the primary national accreditation body for mammography under MQSA, along with State programs in Arkansas and Texas. Iowa ended its own accreditation program on January 1, 2020, so Iowa facilities are accredited by the ACR. Accreditation is separate from certification: the FDA, or a State certifying agency (currently Illinois, Iowa, South Carolina, and Texas), issues the certificate. Accreditation involves clinical image review, phantom image evaluation, and medical physicist survey results. Accreditation must be renewed every three years.

MQSA inspection findings are classified into three levels. Level 1 findings are the most serious: deviations that may seriously compromise the quality of mammography services. Level 2 findings mean performance is generally acceptable, but the facility deviated from standards in ways that may compromise quality. Level 3 findings are minor deviations. According to the FDA's inspection procedures, the facility is asked to respond in writing within 15 working days to a Level 1 finding and within 30 working days to a Level 2 finding, and no response is needed for Level 3. Serious or uncorrected problems can lead to notification of patients and referring providers, suspension or revocation of the certificate, and civil money penalties for willful violations.

The FDA finalized major updates to the MQSA regulations on March 9, 2023, which took effect September 10, 2024. The 2024 Final Rule introduced: mandatory breast density notification in lay letters to all patients (using standardized FDA-approved language); updated medical audit requirements including new tracking metrics; revised personnel qualification standards; and modernized recordkeeping and reporting requirements. The breast density notification requirement was one of the most operationally significant changes for facilities, affecting every lay letter produced.

MQSA does not mandate the use of BI-RADS® specifically, but the ACR's Breast Imaging Reporting and Data System (BI-RADS®) has become the standard lexicon and assessment category framework used in mammography reporting because it satisfies MQSA's requirements for standardized reporting. MQSA requires that reports include a final assessment category that communicates whether additional imaging or biopsy is needed: BI-RADS® categories 0-6 provide the standardized structure for meeting that requirement.

MQSA requires that patients receive a written summary of their mammography results in lay language (plain English rather than medical terminology) within 30 days of their examination, or sooner if the results suggest a need for additional imaging or biopsy. Lay letters must include the final assessment, any recommendation for additional evaluation, and, since the 2024 Final Rule, standardized language about the patient's breast density classification and what it may mean for their screening.

Yes. MQSA applies to all FDA-approved mammography modalities, including full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT). Equipment used for mammography, including 3D tomosynthesis units, must meet MQSA's equipment standards and quality control requirements. Medical physicists perform mammography equipment evaluations under MQSA requirements regardless of modality.

How Mammologix Helps

MQSA Compliance Support for Breast Imaging Centers

Mammologix has supported breast imaging facilities with MQSA-related operational workflows since 1995. Our work spans the areas most directly implicated in MQSA compliance: medical outcome auditing, lay letter preparation and tracking, follow-up documentation, and audit-ready reporting.

Medical Outcome AuditMQSA-aligned audit tracking, performance metric calculation, and interpreting physician outcome reports.Learn more →Lay Letter PreparationCompliant lay letter production including 2024 Final Rule breast density notification language.Learn more →MQSA Policy TemplatesReady-to-use policy templates for mammography quality standards compliance.Learn more →AIR Score CalculatorCalculate your Abnormal Interpretation Rate and benchmark against ACR standards.Learn more →
Talk to Mammologix About MQSA SupportExplore MammoComply

About the Author

RL
Richard D. Lippert, Jr.

Founder, President, and Chief Executive Auditor, Mammologix · Breast Imaging Operations since 1995

A registered radiologic technologist, Richard D. Lippert, Jr., Founder, President, and Chief Executive Auditor of Mammologix, has spent more than 30 years in breast imaging operations, from clinical practice and hospital radiology administration to building specialized service platforms for imaging centers nationwide. His work spans mammography tracking, lay communication, FDA/MQSA-related support, medical outcome audit, and the operational systems that help facilities stay compliant and keep patients from falling through the cracks.

View full bio →

Disclaimer

The content, articles, calculators, tools, estimates, projections, derived data, reports, and other materials provided by Mammologix, LLC, powered by I/O Trak, Inc. (“Mammologix”) are provided for informational and educational purposes only.

The information and outputs provided by Mammologix are not intended to serve as, and should not be relied upon as, medical advice, diagnosis, treatment, clinical guidance, financial advice, investment advice, tax advice, legal advice, accounting advice, or any other professional advice.

Information provided by Mammologix may relate to breast health, mammography, imaging, screening, diagnostics, clinical outcomes, healthcare topics, financial calculations, estimates, projections, or other decision-support information. However, such information should not be used to make personal medical, clinical, financial, investment, business, insurance, legal, or other important decisions without consulting an appropriate qualified professional.

Always seek the advice of a licensed physician, radiologist, healthcare provider, financial advisor, accountant, attorney, or other qualified professional with any questions you may have about a medical condition, screening recommendation, imaging result, treatment option, financial matter, or other professional decision. Never disregard professional medical, financial, legal, or other advice, or delay seeking such advice, because of something you have read, calculated, or received through Mammologix.

Any calculators, formulas, estimates, projections, derived medical outcome data, financial calculations, or other tool-generated outputs are provided as estimates only. Results may be affected by user-entered information, assumptions, formula limitations, incomplete or inaccurate data, rounding, software errors, third-party data, changing medical guidelines, changing financial conditions, changes in law or regulation, or other factors. Mammologix does not represent, warrant, or guarantee that any calculation, output, article, estimate, projection, or derived data is accurate, complete, current, reliable, suitable, or appropriate for any particular purpose.

For medical or health-related content and calculators, Mammologix does not provide medical advice, diagnosis, treatment recommendations, diagnostic interpretation, or patient-specific clinical decision-making. Mammologix content and tools are not a substitute for an in-person evaluation, professional medical consultation, diagnostic interpretation, or individualized care from a licensed healthcare provider. In the event of a medical emergency, contact emergency services or a qualified healthcare provider immediately.

For financial, business, tax, investment, or accounting-related calculators or content, Mammologix does not provide financial, investment, tax, legal, accounting, or business advice. Any outputs are estimates only, and actual results may vary materially based on personal circumstances, market conditions, taxes, fees, interest rates, inflation, risk tolerance, regulatory changes, and other factors.

Use of Mammologix content, articles, calculators, tools, and outputs is at your own risk. You are solely responsible for reviewing, verifying, and interpreting any information or results provided and for obtaining appropriate professional advice before relying on or acting upon such information.

Mammologix assumes no liability for any injury, loss, claim, damage, or expense arising from or related to the use of, reliance on, or inability to use any Mammologix content, article, calculator, tool, estimate, projection, derived data, report, or website material. To the fullest extent permitted by law, Mammologix, its owners, officers, employees, contractors, affiliates, licensors, service providers, and agents disclaim all liability for any direct, indirect, incidental, consequential, special, exemplary, punitive, financial, medical, clinical, business, or other damages arising out of or relating to the use of Mammologix materials or outputs.

The information provided by Mammologix does not establish a doctor-patient, provider-patient, radiologist-patient, financial advisor-client, attorney-client, accountant-client, fiduciary, or other professional relationship.

AI Content Disclosure

Some Mammologix content, calculations, summaries, tools, or outputs may be created, edited, generated, or assisted by artificial intelligence tools or automated systems. While Mammologix may review content for accuracy and relevance, AI-assisted or automated materials may contain errors, omissions, inaccuracies, outdated information, or outputs that are incomplete or inappropriate for a particular user, patient, circumstance, or purpose.

Users should independently verify all AI-assisted content, calculator outputs, and automated results with appropriate qualified professionals before relying on them.

Didn't find what you were looking for?

Our team has supported breast imaging centers since 1995. If it's not here, we probably know the answer.

Ask a Question →